Abstract 2184
Background
The principles of dose-dense (dd) and sequential (s) chemotherapy (CT) were introduced in the adjuvant setting by HeCOG in 1997. We aimed to explore the long-term clinical benefit and safety of treatment of adjuvant dds-CT in patients (pts) with high-risk BC.
Methods
We performed a pooled analysis from 6 HeCOG-initiated clinical trials (3 randomized and 3 observational). Patients with operable, early-stage breast cancer received adjuvant treatment with epirubicin, taxane and cyclophosphamide/methotrexate/ fluorouracil (CMF), except from 297 patients included in one study who did not receive taxanes. Granulocyte colony-stimulating factor was given prophylactically with all treatment regimens. The primary study endpoint was 10-year disease-free survival (DFS) rate.
Results
Between 06/1997 and 04/2013, 4,767 pooled pts were treated with dds-CT (median age 52.9, range 20.9-82.7, postmenopausal: 54%). Patients presented with Hormone receptor (HR)-positive/HER2-negative tumors (56%), HER2-positive tumors (29%) or triple negative breast cancer (TNBC, 15%). Overall, 92.2% of pts completed CT according to study protocol. Grade 4 adverse events were recorded in 356 (8%) pts, mostly neutropenia (81%). Grade 3-4 cardiac adverse events were reported in 6 (0.1%) pts. Six pts succumbed from toxicity during CT including febrile neutropenia (2 pts), acute myocardial infarction (1 pt), infection (1 pt), pulmonary embolism (1 pt) and acute respiratory failure (1 pt). In total, 134 (3%) pts were diagnosed with a secondary cancer; 126 (2.8%) with solid tumors and 16 (0.4%) with a hematologic malignancy. Median follow-up time was 8.9 years (95% CI 8.8-9.1). The 10-year DFS rate was 76% for pts with HR-positive/HER2-negative tumors, 73% with TNBC and 74% for those with HER2-positive tumors (62% and 82% in the pre- and post-trastuzumab era, respectively (p < 0.001).
Conclusions
dds-CT with epirubicin, taxane and CMF in the adjuvant setting was well-tolerated and was associated with favorable clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hellenic Cooperative Oncology Group (HeCOG).
Funding
Hellenic Cooperative Oncology Group (HeCOG).
Disclosure
E. Fountzilas: Travel / Accommodation / Expenses: K.A.M ONCOLOGY / HEMATOLOGY; Travel / Accommodation / Expenses: Merck; Shareholder / Stockholder / Stock options: Deciphera. G. Pentheroudakis: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Leadership role, Research grant / Funding (institution): Roche; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Amgen; Leadership role, Research grant / Funding (institution): Boehringer; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Merck; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Leadership role: Bristol-Myers Squibb; Advisory / Consultancy: MSD; Leadership role: Enorasis. C. Christodoulou: Advisory / Consultancy: Merck; Advisory / Consultancy: Genesis Pharmaceuticals; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Sanofi. A. Koutras: Advisory / Consultancy: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Genesis; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Merck Serono; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Amgen. E. Samantas: Advisory / Consultancy: Merck; Advisory / Consultancy: MSD; Advisory / Consultancy: Asta-Zeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Amgen; Advisory / Consultancy: Genesis. G. Aravantinos: Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: Roche Hellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Genesis Pharma; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer. P. Papakostas: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Genesis Pharmaceuticals. A. Psyrri: Honoraria (institution), Advisory / Consultancy: Amgen; Honoraria (institution), Advisory / Consultancy: Merck Serono; Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Advisory / Consultancy: MSD; Research grant / Funding (institution): Kura. P.A. Kosmidis: Honoraria (self): Novartis; Honoraria (self), Travel / Accommodation / Expenses: MSD; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Genesis. A. Koumarianou: Advisory / Consultancy: Genesis Pharma; Honoraria (self): Pfizer; Speaker Bureau / Expert testimony: Roche; Research grant / Funding (self): Merck; Travel / Accommodation / Expenses: MSD. E. Razis: Honoraria (self), Advisory / Consultancy: Novartis; Travel / Accommodation / Expenses: Genesis Pharmaceuticals; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Genekor. H. Gogas: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): MSD Oncology; Honoraria (institution), Advisory / Consultancy: Amgen; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Pierre-Fabre. G. Fountzilas: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Roche; Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
4413 - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Presenter: Ghassan Abou-Alfa
Session: Poster Display session 2
Resources:
Abstract
4710 - Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Lorenza Rimassa
Session: Poster Display session 2
Resources:
Abstract
5509 - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)
Presenter: Li-Tzong Chen
Session: Poster Display session 2
Resources:
Abstract
1463 - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Presenter: Sylvie Lorenzen
Session: Poster Display session 2
Resources:
Abstract
2392 - GLOW: Randomized Phase 3 Study of Zolbetuximab + CAPOX Compared With Placebo + CAPOX as First-line Treatment of Patients With CLD18.2⁺/HER2⁻ Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Manish Shah
Session: Poster Display session 2
Resources:
Abstract
5217 - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial
Presenter: Rosine Guimbaud
Session: Poster Display session 2
Resources:
Abstract
1726 - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
Presenter: Kenro Hirata
Session: Poster Display session 2
Resources:
Abstract
2279 - FRONTiER: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Presenter: Shun Yamamoto
Session: Poster Display session 2
Resources:
Abstract
4912 - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Jiafu Ji
Session: Poster Display session 2
Resources:
Abstract
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract